Milt G Poll, MD | |
5955 Zeamer Ave, Jber, AK 99506-3702 | |
(907) 580-1815 | |
Not Available |
Full Name | Milt G Poll |
---|---|
Gender | Male |
Speciality | Anesthesiology |
Location | 5955 Zeamer Ave, Jber, Alaska |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1487928107 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | 124525 (Alaska) | Primary |
Mailing Address | Practice Location Address |
---|---|
Milt G Poll, MD 5955 Zeamer Ave, Jber, AK 99506-3702 Ph: (907) 580-1815 | Milt G Poll, MD 5955 Zeamer Ave, Jber, AK 99506-3702 Ph: (907) 580-1815 |
News Archive
Cases of polio have been reported in some African countries that have eradicated the disease, Luis Gomes Sambo, the WHO's Africa regional director, said Monday at the opening of a child immunisation conference in Zimbabwe, Agence France-Presse reports (12/14). It is the WHO's first annual regional conference on immunization, according to VOA News. Sambo said the conference will review the status of immunization in the 46-country sub-Saharan region (Mafundikwa, 12/14).
On January 26, 2011, it was reported that 13 University of Iowa football players were affected so severely by rhabdomyolysis that they were hospitalized. Occurrences of rhabdomyolysis—muscle breakdown—are so rare that it suggests an additional causal factor, such as a drug.
Scientists are reporting an advance toward overcoming a major barrier to tapping the potential of traditional Chinese medicine and India's Ayurvedic medicine in developing new and more effective modern drugs.
UT Southwestern Medical Center researchers have found that a naturally occurring protein - transforming growth factor beta1 (TGF-1) - which normally suppresses the growth of cancer cells, causes a rebound effect after a prolonged exposure.
AcelRx Pharmaceuticals, Inc. today announced that it has completed an End-of-Phase 2 meeting with the US Food and Drug Administration (FDA) for ARX-02, a proprietary Sufentanil NanoTab™ Breakthrough Pain Management System for the treatment of cancer breakthrough pain in opioid-tolerant patients. FDA reviewed a package based on the previously announced positive Phase 2 clinical study results to date for ARX-02 and provided AcelRx with guidance on the Phase 3 program design and NDA requirements.
› Verified 1 days ago
Dr. Fernando Ramiro Tovar, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5955 Zeamer Avenue, 673d Mdg, Jber, AK 99506 Phone: 907-580-1815 | |
Dr. David Austin Bennion Jr., M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 5955 Zeamer Ave, Jber, AK 99506 Phone: 907-580-1842 | |
Dr. Derek David Bradley, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 5955 Zeamer Ave, Jber, AK 99506 Phone: 907-580-7246 | |
Dr. Matthew Christian White, DO Anesthesiology Medicare: Medicare Enrolled Practice Location: 673 Mdg, 5955 Zeamer Ave, Jber, AK 99506 Phone: 907-580-1815 | |
Dr. Aric Dennis Steinmann, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 5955 Zeamer Ave, Jber, AK 99506 Phone: 907-580-2778 | |
Dr. David Allan Mosteller, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5955 Zeamer Ave, Jber, AK 99506 Phone: 210-292-7667 |